Stock analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of ADXS opened at $0.25 on Thursday. Ayala Pharmaceuticals has a 1 year low of $0.14 and a 1 year high of $1.95. The stock has a market capitalization of $2.69 million, a PE ratio of -0.03 and a beta of 1.45. The stock has a 50-day simple moving average of $0.36 and a 200-day simple moving average of $0.58.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share for the quarter.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Read More
- Five stocks we like better than Ayala Pharmaceuticals
- What Are Dividend Challengers?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- What to Know About Investing in Penny Stocks
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- 3 Best Fintech Stocks for a Portfolio Boost
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
